Eli Lilly disclosed additional safety and tolerability data for retatrutide at the annual meeting of the American Diabetes Association and in connection with reporting in The Lancet. The updates included arrhythmia and major cardiovascular complication counts among retatrutide-treated participants versus placebo. The cited figures included arrhythmias in 7 of 403 participants and major cardiovascular complications in 3 treated participants, with none reported in the placebo group. The company’s focus is on refining the safety narrative as retatrutide’s rapid weight-loss profile continues to draw attention across obesity and metabolic disease programs. Clinicians and payers are likely to scrutinize whether the safety pattern changes the risk-benefit framing versus other incretin-class options and upcoming next-generation obesity candidates.